Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026)
Xilio Therapeutics (XLO) reported EBITDA Margin of 111.57% for Q1 2026, up 36116.0% on a YoY basis from N/an in Q1 2025, and down 29.01% sequentially from 86.48% in Q4 2025.
Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 3 years of EBITDA Margin data on file, last reported at 111.57% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 36116.0% year-over-year to 111.57%; the trailing twelve-month figure through Mar 2026 stood at 78.98% (up 53506.0% YoY), and the FY2025 full-year result was 95.92%, up 85903.0% from the prior year.
- EBITDA Margin fell to 111.57% in Q1 2026, from 86.48% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 10.12% in Q3 2025 to a low of 790.55% in Q4 2024.
- A 3-year average of 365.67% and a median of 325.22% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin jumped 70406 bps in 2025 and jumped 36116 bps in 2026, its largest moves.
- Tracing XLO's EBITDA Margin over 3 years: stood at 790.55% in 2024, then soared by 89 bps to 86.48% in 2025, then declined by 29 bps to 111.57% in 2026.
- Business Quant data shows XLO's EBITDA Margin at 111.57% in Q1 2026, 86.48% in Q4 2025, and 10.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -111.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -111.57% |
| Dec 31, 2025 | -86.48% |
| Sep 30, 2025 | -10.12% |
| Jun 30, 2025 | -177.71% |
| Mar 31, 2025 | -472.73% |
| Dec 31, 2024 | -790.55% |
| Sep 30, 2024 | -652.32% |
| Jun 30, 2024 | -623.84% |